Understanding how a new receptor in the immune system responds to cell injury

Immunobiology of a novel human DAMP receptor, its murine homolog, & their ligand

NIH-funded research Univ of Massachusetts Med Sch Worcester · NIH-11132308

This study is looking at a special part of our immune system that helps it respond to damaged cells, and it aims to understand how this part works with a specific protein released when cells are hurt, which could help find new ways to treat conditions like stroke and heart injuries.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniv of Massachusetts Med Sch Worcester NIH-funded
Lab location1 site (Worcester, United States)
Project IDNIH-11132308 on NIH RePORTER

What this research studies

This research investigates a novel receptor in the human immune system that detects signals from damaged cells, known as Damage Associated Molecular Patterns (DAMPs). The study aims to understand how this receptor, along with its mouse counterpart, interacts with a specific ligand called GAPDH, which is released during cell injury. By exploring the mechanisms of this interaction, the research seeks to uncover how these immune responses contribute to both health and disease, particularly in conditions like stroke and cardiac injury. Patients may benefit from insights that could lead to new therapeutic strategies for managing inflammation and tissue damage.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals who have experienced cell injury or conditions related to inflammation, such as stroke or heart attack.

Not a fit: Patients with stable, non-inflammatory conditions or those not experiencing any form of cell injury may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that better manage inflammation and tissue damage in various diseases.

How similar studies have performed: Previous research has shown promising results in understanding DAMPs and their receptors, but this specific receptor and ligand interaction is relatively novel and less explored.

Where this research is happening

Worcester, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancerscell injury
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.